Biotech
Commented by Matthias Schomber on August 25th, 2026 | 06:40 CEST
Evotec, Palantir, dynaCERT: 3 Stocks, 3 Stories — Which One Could Deliver the Best Returns?
Palantir, Evotec and dynaCERT are three companies from different industries. The US-based AI specialist is celebrating a 93% revenue increase and making short sellers bleed. The Hamburg-based biotech group Evotec, on the other hand, is mired in crisis, operating at a loss, and struggling to turn things around through cost-cutting measures. And then there is dynaCERT, which, with its patented hydrogen technology, does not aim to reinvent the diesel engine, but could very well revolutionize it. Which stock could perform the best, and which ones are worth a closer look? Where will boldness be rewarded? We take a closer look for you.
Read
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Stefan Feulner on August 24th, 2026 | 07:50 CEST
Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring
A breakthrough in cancer research sent the stock market into a frenzy last week. For the first time, a personalized mRNA therapy has achieved key endpoints in a large Phase 3 trial, adding billions in market value within hours. At the same time, smaller biotech companies are working on entirely different approaches to target tumors at one of their greatest vulnerabilities. The race for the next generation of cancer treatments is thus gaining momentum. The economic potential is enormous.
Read
Commented by Fabian Lorenz on August 24th, 2026 | 07:45 CEST
Sell Rheinmetall? Evotec with AI Potential and Lahontan Gold's 22% Resource Boost!
Should investors sell Rheinmetall shares? That is the recommendation from mwb research. The analysts continue to view Rheinmetall as a clear operational winner in the European defense boom. However, they believe market expectations starting in 2028 are too ambitious. The company's order backlog is not as robust as many assume. By contrast, there are strong arguments for a rising share price at Lahontan Gold. The gold price climbed back above USD 4,600, suggesting that a new rally in the precious metal could be getting underway—the perfect timing to give the Lahontan story a boost. The company plans to build a mine and begin gold production next year. Most recently, the resource estimate was raised by 22%. And what about Evotec? Its stock is at rock bottom. Can AI-driven optimism provide new momentum?
Read
Commented by Fabian Lorenz on August 24th, 2026 | 07:35 CEST
Share Price Surges and Buy Ratings: New Price Target for Almonty as CTS EVENTIM and BioNTech Stage Comebacks
What a comeback! Almonty's share price surged by more than 50% in August! There are good reasons for the rally. Tungsten is in short supply in the West and is urgently needed due to the ramp-up in weapons production in the US. In addition, Almonty has released convincing quarterly results and announced a share buyback program. Analysts have recently nearly doubled their price target. BioNTech's share price jump of over 25% is less attributable to the biotech company itself; the stock has benefited from the breakthrough achieved by rival Moderna. Meanwhile, long-term performer CTS EVENTIM also made a comeback last week. Does this mean the stock is returning to its long-term uptrend? Analysts recommend the share as a "Buy".
Read
Commented by Matthias Schomber on August 21st, 2026 | 08:50 CEST
Short Squeeze, Takeover Battle and Military Contract – Why Novavax, Commerzbank and HPQ Silicon Could Electrify the Markets!
Three stocks, three opportunities. While Novavax could be heading for a short squeeze, aided by peer Moderna and a high short-interest ratio, a decisive turning point could be emerging in Commerzbank's multibillion-euro takeover battle with UniCredit. Away from these two companies, the greentech specialist HPQ Silicon is celebrating an operational milestone with its first military contracts for its new battery cells and is positioning itself for a technical breakout. Where do the greatest return potentials lie, and what should investors know right now? We provide the answers.
Read
Commented by Stefan Bode on August 21st, 2026 | 07:30 CEST
Three Stocks, Three Themes: Rally, Crash, and Comeback Potential—Lahontan Gold, Moderna and PFISTERER
Record profits, yet double-digit share price losses. On the stock market, it is not just earnings that count—it is the outlook for the future. That is precisely where some of the most interesting opportunities can emerge. We highlight a cyclical infrastructure stock with slowing momentum, a biotech company following a major medical breakthrough, and a commodities player benefiting from higher gold prices and project progress. Investors looking to determine whether these moves reflect market overreaction or genuine new developments will find the decisive signals in the numbers and outlooks.
Read
Commented by Carsten Mainitz on August 19th, 2026 | 07:55 CEST
Weight-Loss Boom 2.0: BioNxt Solutions, Novo Nordisk and Nestlé Are Growing in a Billion-Dollar Market
The weight-loss injection has not only transformed the pharmaceutical market but is also gradually impacting the food industry. The prescription drug semaglutide, used to treat type 2 diabetes and obesity, is at the forefront of this trend. The active ingredient mimics the body's own gut hormone GLP-1, thereby achieving several desired effects. It increases feelings of fullness, reduces appetite, slows gastric emptying, and improves insulin secretion. Meanwhile, innovative specialists such as BioNxt Solutions are positioning themselves by advancing alternative and improved drug delivery methods. The Canadian company is developing thin films of active ingredients that dissolve under the tongue and are intended to replace medications administered via injection or traditional tablets. The news flow is promising. At the same time, Nestlé is creating a new food category for people who want to lose weight using GLP-1 preparations. Who has the edge?
Read
Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST
Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca
According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.
Read
Commented by Jens Castner on August 13th, 2026 | 08:00 CEST
Berkshire Hathaway, Novo Nordisk & Zefiro Methane: Do Good and Profit From It – Up to 250% Potential!
Berkshire Hathaway and Novo Nordisk have clearly exceeded expectations with their latest quarterly results. We take a closer look at these two heavyweights—and in the process, we also turn our attention to a small environmental services provider that, according to analysts, could offer significant potential for a tenfold return. Zefiro Methane embodies one of Warren Buffett's mottos particularly closely: do good and talk about it—or, even better, do good and make money from it.
Read